Seres Therapeutics Inc (MCRB)

Over the past six months, Seres Therapeutics' stock price has experienced a decline. Key events impacting the stock include the report of fourth quarter and full year 2025 financial results and business updates, the appointment of Richard N. Kender as Executive Chair and interim CEO, a strategic workforce reduction of approximately 30% and a prioritization of its emerging programs, publications highlighting VOWST™'s mechanism of action, and third-quarter 2025 financial results and business updates. Analyst ratings have varied, with a consensus rating of "Hold" and a target price of $14.00.

There is no inherent demand seasonality for Seres Therapeutics' products and services. The demand for such therapeutics is driven by medical need and clinical outcomes rather than seasonal patterns.

Seres Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing live biotherapeutics to treat diseases by modulating the human microbiome. The company's core business involves developing microbiome-derived therapeutics designed to modulate the gut microbiome to restore health. Seres Therapeutics pioneered the development and FDA approval of VOWST™, which was subsequently divested to Nestlé Health Science in September 2024. Currently, Seres Therapeutics is prioritizing its inflammatory and immunology biotherapeutics portfolio, including SER-155, SER-603 and SER-147.

Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States, and its sales are primarily generated in the United States.

In the past year, Seres Therapeutics' brand reputation has been influenced by both positive scientific advancements and financial challenges. Publications highlighting the mechanism of action of VOWST™ and FDA designations for SER-155 contributed positively. However, the company's financial situation, including a "going concern" warning and workforce reduction, could negatively impact its brand reputation.

Seres Therapeutics, Inc. has a mixed ownership structure, with institutional, insider, and individual investors. Institutional investors hold approximately 13.23% to 25.47% of the company's stock. Insiders own approximately 1.90% to 700.29% of the stock. Individual investors hold a significant stake, ranging from 52% to 76.15% of the company.